{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:26:23Z","timestamp":1761895583002},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,1,21]],"date-time":"2013-01-21T00:00:00Z","timestamp":1358726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet. Med."],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>To compare the effect of insulin degludec and insulin glargine on health\u2010related quality of life in patients with Type\u00a02 diabetes starting on insulin therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patient\u2010level data from three open\u2010label, randomized, treat\u2010to\u2010target trials of 26 or 52\u00a0weeks' duration were pooled using a weighted analysis in conjunction with a fixed\u2010effects model. Insulin\u2010naive patients received either insulin degludec (<jats:italic>n<\/jats:italic>\u00a0=\u00a01290) or insulin glargine (<jats:italic>n<\/jats:italic>\u00a0=\u00a0632) once daily, in combination with oral anti\u2010diabetic drugs. Glycaemic control was assessed via HbA<jats:sub>1c<\/jats:sub>and fasting plasma glucose concentrations. Rates of hypoglycaemia, defined as plasma glucose &lt;\u00a03.1\u00a0mmol\/l (&lt;\u00a056\u00a0mg\/dl), were recorded. Health\u2010related quality of life was evaluated using the 36\u2010item Short Form (<jats:styled-content style=\"fixed-case\">SF<\/jats:styled-content>\u201036<jats:sup>\u00ae<\/jats:sup>) version\u00a02 questionnaire. Statistical analysis was performed using a generalized linear model with treatment, trial, anti\u2010diabetic therapy at baseline, gender, region and age as explanatory variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Insulin degludec was confirmed as non\u2010inferior to insulin glargine based on HbA<jats:sub>1c<\/jats:sub>concentrations. In each trial comprising the meta\u2010analysis, fasting plasma glucose and confirmed overall and nocturnal (00.01\u201305.59\u00a0h) hypoglycaemia were all numerically or significantly lower with insulin degludec vs. insulin glargine. At endpoint, the overall physical health component score was significantly higher (better) with insulin degludec vs. insulin glargine [+0.66 (95%\u00a0<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>0.04\u20131.28)], largely attributable to a difference [+1.10 (95%\u00a0<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>0.22\u20131.98)] in the bodily pain domain score. In the mental domains, vitality was significantly higher with insulin degludec vs. insulin glargine [+0.81 (95%\u00a0<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>0.01\u20131.59)].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Compared with insulin glargine, insulin degludec leads to improvements in both mental and physical health status for patients with Type\u00a02 diabetes initiating insulin therapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dme.12086","type":"journal-article","created":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T15:04:09Z","timestamp":1354374249000},"page":"226-232","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Insulin degludec improves health\u2010related quality of life (SF\u201036<sup>\u00ae<\/sup>) compared with insulin glargine in people with Type\u00a02 diabetes starting on basal insulin: a meta\u2010analysis of phase\u00a03a trials"],"prefix":"10.1111","volume":"30","author":[{"given":"N.","family":"Freemantle","sequence":"first","affiliation":[{"name":"Department of Primary Care and Population Health UCL Medical School London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Meneghini","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes University of Miami Miller School of Medicine Miami FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Christensen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S S\u00f8borg Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. L.","family":"Wolden","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S S\u00f8borg Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Jendle","sequence":"additional","affiliation":[{"name":"School of Health and Medical Sciences \u00d6rebro University \u00d6rebro Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ratner","sequence":"additional","affiliation":[{"name":"American Diabetes Association Alexandria VA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,21]]},"reference":[{"key":"e_1_2_4_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-7560(199905\/06)15:3<205::AID-DMRR29>3.0.CO;2-O"},{"key":"e_1_2_4_12_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2001.45029.x"},{"key":"e_1_2_4_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01838.x"},{"key":"e_1_2_4_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"e_1_2_4_12_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.11.2673"},{"key":"e_1_2_4_12_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1348"},{"key":"e_1_2_4_12_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.5.1066"},{"key":"e_1_2_4_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2009.02.005"},{"key":"e_1_2_4_12_10_1","volume-title":"Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation","author":"Patrick DL","year":"1993"},{"key":"e_1_2_4_12_11_1","volume-title":"User's Manual for the SF\u201036v2 Health Survey","author":"Ware JE","year":"2007"},{"key":"e_1_2_4_12_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-012-0739-z"},{"key":"e_1_2_4_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01627.x"},{"key":"e_1_2_4_12_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1905"},{"key":"e_1_2_4_12_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1925"},{"key":"e_1_2_4_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62305-7"},{"key":"e_1_2_4_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60205-0"},{"key":"e_1_2_4_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2011.03547.x"},{"key":"e_1_2_4_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01232.x"},{"key":"e_1_2_4_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60204-9"},{"key":"e_1_2_4_12_21_1","article-title":"Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre\u2010planned meta\u2010analysis of phase 3 trials","author":"Ratner RE","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"e_1_2_4_12_22_1","doi-asserted-by":"crossref","unstructured":"BergenstalR BhargavaA JainR UngerJ RasmussenS MersebachHet\u00a0al.200\u00a0U\/mL insulin degludec improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin\u2010na\u00efve people with type\u00a02 diabetes. Presented at AACE 21st Annual Scientific and Clinical Congress Philadelphia PA May 2012: A26. Available athttp:\/\/am.aace.com\/sites\/all\/files\/abstract-2012.pdfLast accessed 23 July 2012.","DOI":"10.1016\/j.jcjd.2012.07.397"},{"key":"e_1_2_4_12_23_1","first-page":"A272","article-title":"Insulin degludec improves glycemic control in insulin\u2010na\u00efve patients with type\u00a02 diabetes: results of a randomized pan\u2010Asian trial","volume":"61","author":"Onishi Y","year":"2012","journal-title":"Diabetes"},{"key":"e_1_2_4_12_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1205"},{"key":"e_1_2_4_12_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_2_4_12_26_1","doi-asserted-by":"publisher","DOI":"10.1109\/TAC.1974.1100705"},{"key":"e_1_2_4_12_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.5.639"},{"key":"e_1_2_4_12_28_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/oso\/9780198527695.001.0001","volume-title":"Assessing Quality of Life in Clinical Trials: Methods and Practice","author":"Fayers PM","year":"2005"},{"key":"e_1_2_4_12_29_1","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2008.793"},{"key":"e_1_2_4_12_30_1","first-page":"CD005613","article-title":"Long\u2010acting insulin analogues versus NPH insulin (human isophane insulin) for type\u00a02 diabetes mellitus","volume":"18","author":"Horvath K","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_4_12_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.277.1.63"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdme.12086","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.12086","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dme.12086","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.12086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T08:13:20Z","timestamp":1714637600000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.12086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,21]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/dme.12086"],"URL":"https:\/\/doi.org\/10.1111\/dme.12086","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,21]]},"assertion":[{"value":"2012-08-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-11-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-01-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}